TD Waterhouse Canada Inc. reduced its stake in Merck & Co., Inc. (NYSE:MRK – Free Report) by 11.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 354,395 shares of the company’s stock after selling 43,595 shares during the period. TD Waterhouse Canada Inc.’s holdings in Merck & Co., Inc. were worth $44,466,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in MRK. Kingdom Financial Group LLC. acquired a new position in shares of Merck & Co., Inc. in the 4th quarter valued at $25,000. Abound Financial LLC purchased a new position in shares of Merck & Co., Inc. in the 4th quarter valued at $26,000. Prosperity Bancshares Inc acquired a new stake in Merck & Co., Inc. during the 4th quarter worth $26,000. High Note Wealth LLC raised its stake in Merck & Co., Inc. by 58.9% during the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock worth $31,000 after acquiring an additional 109 shares in the last quarter. Finally, IFC & Insurance Marketing Inc. purchased a new stake in Merck & Co., Inc. in the fourth quarter valued at $31,000. Institutional investors and hedge funds own 76.07% of the company’s stock.
Merck & Co., Inc. Stock Up 0.4%
MRK opened at $152.32 on Friday. Merck & Co., Inc. has a 52 week low of $77.58 and a 52 week high of $156.92. The business has a 50 day moving average price of $134.20 and a two-hundred day moving average price of $123.33. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22. The company has a market cap of $375.80 billion, a PE ratio of 121.86, a P/E/G ratio of 6.60 and a beta of 0.21.
Merck & Co., Inc. Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be given a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date is Tuesday, September 15th. Merck & Co., Inc.’s dividend payout ratio (DPR) is 272.00%.
Wall Street Analysts Forecast Growth
Several equities analysts have issued reports on MRK shares. JPMorgan Chase & Co. upped their price objective on shares of Merck & Co., Inc. from $135.00 to $140.00 and gave the company an “overweight” rating in a research note on Monday, July 13th. Argus boosted their target price on Merck & Co., Inc. from $145.00 to $170.00 and gave the company a “buy” rating in a report on Tuesday, August 25th. Bank of America boosted their target price on Merck & Co., Inc. from $130.00 to $141.00 and gave the company a “buy” rating in a report on Tuesday, June 30th. Scotiabank raised their price target on Merck & Co., Inc. from $136.00 to $155.00 and gave the stock a “sector outperform” rating in a research note on Tuesday, June 30th. Finally, The Goldman Sachs Group raised their price target on Merck & Co., Inc. from $140.00 to $160.00 and gave the stock a “buy” rating in a research note on Friday, August 21st. Fifteen research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $147.60.
Read Our Latest Report on Merck & Co., Inc.
Insider Transactions at Merck & Co., Inc.
In other news, EVP Jennifer Zachary sold 80,315 shares of the firm’s stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $133.46, for a total value of $10,718,839.90. Following the completion of the sale, the executive vice president owned 45,509 shares in the company, valued at approximately $6,073,631.14. This trade represents a 63.83% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Richard R. Deluca sold 20,784 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $130.43, for a total transaction of $2,710,857.12. Following the completion of the sale, the executive vice president owned 134,703 shares of the company’s stock, valued at $17,569,312.29. This trade represents a 13.37% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 228,238 shares of company stock worth $29,977,783 over the last quarter. 0.17% of the stock is currently owned by corporate insiders.
Merck & Co., Inc. Profile
Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.
Founded in the late 19th century as the U.S.
Featured Stories
- Five stocks we like better than Merck & Co., Inc.
- The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story
- NVIDIA’s Hugging Face Deal Raises a Bigger Question About Its AI Moat Now
- Dropping the Dough: Yum! Brands Strategically Trims the Fat
- These 3 Stock Charts Just Flashed the Dreaded Death Cross Pattern
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
